Site-specific IGFBP-1 hyper-phosphorylation in fetal growth restriction: clinical and functional relevance

Majida Abu Shehab1, Javad Khosravi, Victor K M Han

  • 1Department of Pediatrics, University of Western Ontario, Ontario, Canada.

Insights

Increased phosphorylation of Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) in fetal growth restriction (FGR) limits Insulin-like Growth Factor-I (IGF-I) bioavailability. This suggests a key mechanism contributing to FGR development.

Area of Science:

  • Endocrinology
  • Reproductive Biology
  • Molecular Biology

Background:

  • Insulin-like Growth Factor-I (IGF-I) bioavailability is crucial for fetal growth.
  • IGF-I bioavailability is regulated by IGF-binding proteins (IGFBPs), particularly IGFBP-1.
  • Phosphorylation of IGFBP-1 can alter its binding affinity to IGF-I.

Purpose of the Study:

  • To investigate if site-specific IGFBP-1 phosphorylation patterns differ in fetal growth restriction (FGR).
  • To determine the correlation between IGFBP-1 phosphorylation and fetal growth parameters.
  • To explore the impact of altered IGFBP-1 phosphorylation on IGF-I binding.

Main Methods:

  • Comparison of IGFBP-1 phosphorylation sites and degree in amniotic fluid from FGR and control groups.
  • Liquid chromatography-tandem mass spectrometry (LC-MS/MS) for phosphopeptide analysis.
  • Surface plasmon resonance (BIAcore) to assess IGFBP-1/IGF-I binding kinetics.
  • Structural modeling to predict the impact of phosphorylation on IGF-I interaction.

Main Results:

  • Serine phosphorylated IGFBP-1 concentration negatively correlated with birth weight in FGR.
  • Significantly higher phosphorylation intensities at Ser101, Ser98/Ser101, and Ser169 in FGR compared to controls.
  • Increased IGFBP-1 association and decreased dissociation rates with IGF-I in FGR, indicating tighter binding.

Conclusions:

  • Elevated site-specific phosphorylation of IGFBP-1, particularly at Ser98, Ser101, and Ser169, is characteristic of FGR.
  • This increased phosphorylation likely enhances IGFBP-1's affinity for IGF-I, reducing IGF-I bioavailability.
  • The findings suggest that altered IGFBP-1 phosphorylation is a significant contributor to the pathophysiology of FGR.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...